Fibromodulin: From Matrisome Architecture to Master Regulator of Cellular Fate.

Transitioning from its traditional conceptualization as a static scaffold, the extracellular matrix (ECM) is now recognized as a dynamic regulatory hub that integrates biomechanical cues with biochemical signaling to dictate cellular fate and physiological stability. Central to this regulatory network is Fibromodulin (FMOD), a Class II small leucine-rich proteoglycan (SLRP) that integrates structural scaffolding with complex signaling modulation. This review synthesizes the molecular topography of FMOD, detailing how its signature horseshoe-shaped solenoid fold facilitates high-affinity docking with type I and II collagens to orchestrate fibrillogenesis. We delineate FMOD's dual functionality as a structural architect, responsible for matrix tensile integrity, and as a biochemical supervisor that sequesters and titrates growth factor bioavailability, specifically within the transforming growth factor-beta (TGF-β) superfamily. Under physiological conditions, FMOD-mediated matrix organization is essential for musculoskeletal resilience and ocular transparency; however, its dysregulation functions as a context-dependent amplifier and modifier of tissue pathology. We analyze the mechanistic shift where FMOD promotes aberrant collagen cross-linking in fibrotic visceral organs, contrastingly drives scleral thinning in myopia, and facilitates the assembly of a desmoplastic "stromal shield" within the tumor microenvironment. Furthermore, the ectopic overexpression of FMOD in B-cell chronic lymphocytic leukemia (B-CLL) highlights its clinical utility as a highly specific diagnostic biomarker and a viable target for TCR-based immunotherapies. By linking biomechanical cues to intracellular cascades, FMOD serves as a critical rheostat of the matrisome, offering a unique molecular target to disrupt pathological stroma and restore tissue homeostasis.